The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Migraine is recognized globally as the seventh most disabling condition across all diseases, accounting for approximately 2.9% of all years lived with disability (YLDs). It is also the top cause of ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

The risk of mortality among older adults hospitalized with influenza was significantly lower among those who received oseltamivir vs no antiviral therapy.